Adenine: an important drug scaffold for the design of antiviral agents  by Wang, Changyuan et al.
Institute of Materia Medica, Chinese Academy of Medical Sciences
H O S T E D  B Y Chinese Pharmaceutical Association
www.elsevier.com/locate/apsb
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2015;5(5):431–441http://dx.doi.org/10.10
2211-3835 & 2015 Ch
Elsevier B.V. This is
nCorresponding auth
E-mail address: x
Peer review under rwww.sciencedirect.comREVIEWAdenine: an important drug scaffold
for the design of antiviral agentsChangyuan Wang, Zhendong Song, Haiqing Yu, Kexin Liu,
Xiaodong ManCollege of Pharmacy, Dalian Medical University, Dalian 116044, China
Received 11 March 2015; received in revised form 2 April 2015; accepted 29 April 2015KEY WORDS
Antiviral;
Structure–activity rela-
tionship;
Adenine;
Acyclic nucleoside phos-
phonates;
Scaffold16/j.apsb.2015.07.00
inese Pharmaceutica
an open access artic
or. Tel./fax: þ86 4
iaodong.ma@139.co
esponsibility of InstAbstract Adenine derivatives, in particular the scaffold bearing the acyclic nucleoside phosphonates
(ANPS), possess signiﬁcant antiviral and cytostatic activity. Till now, several effective adenine derivatives
have been marketed for the treatment of HIV, HBV, CMV and other virus-infected diseases. These
compounds are represented by tenofovir (PMPA), a medicine for both HIV and HBV, and adefovir as an
anti-HBV agent. More than this, other analogs, such as GS9148, GS9131, and GS7340, are also well-
known anti-viral agents that have been progressed to the clinical studies for their excellent activity. In
general, the structures of these compounds include an adenine nucleobase linked to a phosphonate side
chain. Considerable structural modiﬁcations on the scaffold itself and the peripheral sections were made.
The structure-activity relationships (SARs) of this skeleton will provide valuable clues to identify more
effective adenine derivatives as antiviral drugs. Here, we systematically summarized the SARs of the
adenine derivatives, and gave important information for further optimizing this template.
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Human immunodeﬁciency virus (HIV), Rauscher murine sarcoma
virus (R-MuLV), herpes simplex virus (HSV), cytomegalovirus
(CMV), feline immunodeﬁciency virus (FIV), Epstein-Barr virus
(EBV), hepatitis B virus (HBV) and hepatitis C virus (HCV) are
highly contagious viruses endangering human health. Being the
most important antiviral agents, acyclic nucleoside phosphonates
(ANPS) play a signiﬁcant role in the treatment of virus-infected
diseases. In particular, adenine derivatives bearing the adenine
nucleuses possess excellent antiviral activity against most of
the double-stranded DNA viruses, such as the herpes group
viruses and the orthopoxviruses1,2. Previous SARs explorations
proved that the concept of using the ANPs as chain terminators
for antiviral was remarkably effective (1, Fig. 1)3,4. A large
number of adenine derivatives have been discovered as potential
antiviral agents motivated by this hypothesis. For example, the
novel agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA, ade-
fovir, 2, Fig. 1) was approved for the treatment of hepatitis B virus
(HBV) infections by the US FDA in 20025–7, while the (R)-9-
[(phosphonomethoxy)propyl]adenine ((R)-PMPA, tenofovir, 3,
Fig. 1) was launched in the US market as a prodrug (tenofovir
disoproxil fumarate, TDF) for the treatment of HIV infections in
2001 and for the treatment of HBV in 2008, respectively8.
Besides, several adenine derivatives also have progressed to
clinical exploration, such as GS91489–11 (4, Fig. 1), GS913112
(5, Fig. 1), and GS734013,14 (6, Fig. 1). Undoubtedly, adenine
derivatives are the most valuable inhibitors for the development of
antiviral agents.
Through a key phosphate–carbon–oxygen bond, the adenine
nucleobase of this template is attached to a phosphonate group,
making these compounds more stable than those that contain the
phosphate–oxygen–carbon bond of a phosphate group. Therefore,
compounds containing the phosphate–carbon–oxygen linker
achieve higher levels of the active metabolites in the cells.
Moreover, they also possess a broad activity spectrum that also
includes RNA viruses and retroviruses. However, owing to theFigure 1 Structures of the novel apoor oral bioavailability caused by the negatively charged phos-
phonate moiety, the therapeutic use of these nucleoside phospho-
nates was limited15. In order to obtain the neutral and membrane-
permeable prodrugs, great attention has been paid to the optimiza-
tion of this template, and several highly potent virus inhibitors
have been successfully produced. A thorough analysis of the SARs
of this scaffold will provide useful clues for further structural
optimization, which is achieved in this review.2. Adenine nucleus
Adenine analogs 7 and 8 (Fig. 2) bearing a chlorine atom at the C-2
position of the adenine nucleus were synthesized by several
groups16–19. Surprisingly, only by introducing this atom, the
newly obtained compounds did not possess any anti-virus activity
at all. Instead, they were effective as chemotherapeutic agents for
the treatment of refractory chronic leukemia and hairy cell
leukemia. The methylsulfanyl analogs (9–11, Fig. 2) produced
similar results. These compounds exhibited a weaker agonistic
activity toward the P2Y1 receptor20.
The diamino-substituted (C-2 and C-6 positions) analogs 12 and
13 (Fig. 3) containing a triﬂuoromethyl group at the side chain were
originally synthesized by Dvorá̌ková in 199421. Neither exhibited
desired antiviral properties. Also, the addition of a ﬂuorine atom to
the C-2 position (analog 14) (Fig. 3) reduced the antiviral activity
against both the RNA viruses and the DNA viruses. The similar trend
of decreasing antiviral activity was observed in the case of the
tenofovir analogs, where the compound 15 (Fig. 3) completely lacked
antiretroviral properties. Whereas the bis(amidate) prodrug 16 (Fig. 3)
was moderately active against HIV-1 (EC50¼5.51 μmol/L), probably
due to its improved bioavailability22. All these suggested that
modifying the C-2 position of the adenine nucleus was utterly
ineffective for improving the antiviral potency.
Analogs 17a–e (Fig. 4) and 18–21 (Fig. 4) bearing a ﬂuorine
atom at the C-6 position of the nucleus bases were synthesized as
antiviral agents by several companies23,24, but their activity wasdenine derivatives as antiviral agents.
Figure 3 Adenine derivatives with substituents (NH2, F) at the C-2 position.
Figure 2 Adenine derivatives with substituents (Cl, MeS) at the C-2 position.
Figure 4 Adenine derivatives with substituents (NH2, F) at the C-6 position.
Adenine: an important drug scaffold for antiviral agents 433not reported. Compound 22 (Fig. 4) that contains a heptaﬂuoro-
propyl moiety at the C-6 position of the adenine ring was active
against various viruses, such as HSV-1 (MIC50¼21.8 μmol/L),
HSV-2 (MIC50¼7.3 μmol/L), HSV-1 TK (MIC50¼4.4
μmol/L) in E6SM cells and against CMV (MIC50¼3.6
μmol/L) and varicella-zoster virus (VZV) TK and TKþ mutants
(MIC50¼0.6–1.3 μmol/L) in HEL cells. Unfortunately, compound22 also was highly cytotoxic in the host cells at concentrations
above 45 μmol/L25.
In 2008, a series of analogs with 9-, 7- and 3-substituted 2-
or 6-guanidinopurines were prepared and evaluated for their
biological activity by C̈esnek (23 and 24, Fig. 5)26. Unfortu-
nately, none of these compounds exhibited signiﬁcant antiviral
activity.
Figure 5 Adenine derivatives with substituents at the C-6 position.
Table 1 Structures and activities of lipid esters of HPMPA.
Compd. EC50 (mmol/L)
a
HCMV MCMV Vaccinia Cowpox
CDV 1.2 0.04 25.3 30.7
(S)-HPMPA 0.82 0.16 2.7 4.0
25a 0.003 0.002 0.01 0.02
25b 0.003 0.003 0.01 0.02
25c 0.003 0.04 0.003 0.007
25d 0.003 0.1 0.018 0.034
aAnti-HIV-1 activity (EC50): 50% effective concentration in
wild-type CEM cell cultures.
Changyuan Wang et al.4343. Side chain
3.1. Linear linker
To improve the oral bioavailability of the novel 9-(S)-(3-
Hydroxy-2-phosphonomethoxypropyl)adenine ((S)-HPMPA),
Hostetler27 prepared orally bioavailable lipid esters of (S)-
HPMPA 25a–d (Table 1) and evaluated their antiviral activity
against human cytomegalovirus (HCMV), murine cytomegalo-
virus (MCMV), vaccinia (VV), and cowpox viruses (CV).
Among them, oleyloxyethyl-(S)-HPMPA (HDP-(S)-HMPA,
25a) was the most active inhibitor, possessing the EC50 values
of 0.003 μmol/L against HCMV and 1.4 μmol/L for unmodiﬁed
HPMPA, respectively. In cells infected with VV and CV,
octadecyloxyethyl-(S)-HPMPA had EC50 values of 0.01,
0.02 μmol/L vs. 2.7, 4.0 μmol/L for unmodiﬁed HPMPA,
respectively. Compared with the alkoxyalkyl esters of cidofovir,
the corresponding alkoxyalkyl esters of (S)-HPMPA displayed
equivalent activity against HCMV and MCMV, in parallel with
15- to 20-fold higher activity against VV and CV in vitro.
Obviously, the alkoxyalkyl esters of (S)-HPMPA are worthy of
further investigation for treatment of infections caused by
herpes viruses and orthopoxviruses.
In contrast to the previous observation that the acyclic nucleo-
side phosphonates were only active against double stranded DNA
viruses, HIV and HBV, Valiaeva found that octadecyloxyethyl 9-
(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine (26, ODE-
(S)-MPMPA, Table 2) was also able to suppress both genotype 1b
and 2a hepatitis C virus (HCV) replicons with an EC50 value of
1–2 μmol/L and a CC50 value of more than 150 μmol/L, respec-
tively28. From the SARs exploration, it also can be seen that
analogs (26–30, Table 2) with substitutions at the hydroxyl group
larger than a methyl or ethyl group, or with other adenine bases
were less active, but most compounds had signiﬁcant antiviral
activity against HIV-1 in vitro. One peculiar compound was
octadecyloxyethyl 9-(R)-[3-methoxy-2-(phosphonomethoxy)pro-
pyl]guanine (27, ODE-(R)-MPMPA, Table 2), which possesses
an EC50 value of less than 0.01 μmol/L along with a selectivity
index of more than 4.4 million.
In 2010, Krecmerov29 identiﬁed 9-(S)-[3-Hydroxy-2-(phos-
phonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP, 31,
Fig. 6) and its cyclic analogs as potential drug candidates
(33–35, Fig. 6) against the poxvirus infections. To improve the
bioavailability of these compounds, a series of diverse ester
prodrugs, including alkoxyalkyl (hexadecyloxypropyl, octade-
cyloxyethyl, hexadecyloxyethyl), pivaloyloxymethyl (POM),2,2,2-triﬂuoroethyl, butylsalicylyl, and prodrugs based on
peptidomimetics were synthesized. All these compounds were
evaluated for the activity against vaccinia virus and other herpes
viruses. This contribution resulted in alkoxyalkyl ester deriva-
tives of HPMPDAP, with 50% effective concentrations that
were 400–600-fold lower than those of the parent compound.
While prodrugs with 2,2,2-triﬂuoroethyl, POM, and butylsali-
cylyl, were able to inhibit vaccinia virus replication at 50%
effective concentrations that were equivalent or 10-fold lower
than those observed for the parent compounds.3.2. Amide linker
Amide prodrugs of PMEA were ﬁrst synthesized as anti-HIV
agents by Starrett30 in 1994. However, the obtained compounds
were unstable under acidic conditions and provided levels of
PMEA comparable to the parent compound after oral
Table 2 Another series of structures and activities of lipid esters of MPMPA.
Compd. R1 R2 Abbreviation EC50
a CC50
b SIc
BM4–5(1b) JFH-1(2a) BM4-5(1b) JFH-1(2a)
26 Me (S) ODE ODE-(S)-MPMPA 1.43 2.38 4150 4105 463
27 Me (R) ODE ODE-(R)-MPMPA 4.65 5.33 4150 432.3 428.1
28 Me (S) HDP HDP-(S)-MPMPA 2.36 4.64 4150 463.6 432.3
29 Et (R,S) HDP HDP-(R,S)-EPMPA 7.59 8.87 99 13.0 11.1
30 i-Pr (R,S) HDP HDP-(R,S)-IPMPA 5.12 98.8 100 3.14 —
aAnti-HIV-1 activity (EC50): 50% effective concentration in wild-type CEM cell cultures (μmol/L).
bCC50: cytotoxic concentration (μmol/L).
cSelectivity index (SI)¼CC50/EC50.
Adenine: an important drug scaffold for antiviral agents 435administration. In 1997, Ballatore31 prepared another series of
amidate prodrugs 36a–k (Table 3), and tested their activity
in vitro. Of these compounds, prodrug 36c displayed tremendously
enhanced antiviral potency compared with the parent nucleotide
analog. Enzymatic studies in vitro and structure–activity relation-
ships indicated that the releasing mechanism of such prodrugs may
be the same as that described for the phosphoramidate triesters of
nucleotide analogs.
In the same year, Chapman13 discovered a novel amidate
derivative GS7340 (6, Fig. 1). The EC50 of GS 7340 against
human immunodeﬁciency virus type 1 in MT-2 cells was
0.005 μmol/L compared to an EC50 of 5 μmol/L for the parent
drug tenofovir. The L-alaninyl analog (GS7340) was 41000-fold
more active than the D-alaninyl analog. Moreover, it has a half-life
of 90 min in human plasma and a half-life of 28.3 min in an MT-2
cell, respectively. The antiviral activity and the metabolic stability
in MT-2 cell extracts and plasma were also sensitive to the
stereochemistry at the phosphorus. After a single oral dose of GS
7340 (10 mg/kg of tenofovir) to male beagle dogs, the plasma
level of tenofovir was 17% of that achieved by an intravenous
dose of tenofovir. The total intracellular concentration of all
tenofovir-containing species in isolated peripheral blood mono-
nuclear cells was 63 μg/mL compared to 0.2 μg/mL in plasma. In
addition, a radiolabeled distribution study with dogs was carried
out and an increased distribution of tenofovir to tissues of
lymphatic origin compared to the commercially available prodrug
tenofovir DF (Viread) was found. Overall, owing to these excellent
properties, GS7340 are being tested in a phase III clinical
study now.
Recently, Meier designed two new classes of lipophilic
prodrugs of PMEA32. The ﬁrst series of compounds 37a–d
(Table 4) were prepared based on the cycloSal nucleotide
approach. Because of the surprisingly low hydrolysis stability of
these cycloSal–PMEA derivatives, more stable derivatives were
designed. Instead of using salicyl alcohol, in cycloAmb–PMEA
derivatives, 2-aminobenzyl alcohols were attached to PMEA (38a–c,
Table 4). The latter compounds exhibited a considerably higherstability compared to the cycloSal counterparts. Stability studies
uncovered that all lipophilic prodrugs delivered PMEA selectively by
chemical means. Moreover, none of these compounds proved to
inhibit acetyl- and butyrylcholinesterase, and some of the phospho-
nate diesters were even more active against HIV than parent PMEA.
3.3. Borano linker
In 2006, Barral et al.33 synthesized two boranophosphonate
nucleosides, 9-[2-(boranophosphonomethoxy)ethyl]adenine (39a,
Table 5) and (R)-9-[2-(ranophosphonomethoxy)propyl]adenine
(39b, Table 5). Both H-phosphinates 39a and 39b, and boranopho-
sphonates 40a and 40b were evaluated for their in vitro activity
against HIV infected cells and a panel of DNA or RNA viruses. It
was unfortunate that none of them exhibited signiﬁcant antiviral
activity in vitro and cytotoxicity. A decomposition study revealed
that the boranophosphonates 40a and 40b were metabolized in
culture medium into H-phosphinates 39a and 39b, with half-live
values of 5.3 h for 40a and 1.3 h for 40b, respectively.
Carbocyclic phosphonate analogs of dideoxy-adenine nucleo-
tides were discovered as potential anti-HIV inhibitors by Wolff-
Kugel and Halazy34 as early as 1991. With the aim to improve the
metabolic stability, the sugar ring oxygen atom in dideoxyadeno-
sine monophosphate (ddAMP, 41, Fig. 7) was replaced by a
methylene and labile phosphate group was replaced by an α,α-
(diﬂuoromethylene)phosphonate35. Biological test disclosed that
analog 42 (Fig. 7) was not a substrate of AMP kinase (myoki-
nase)36–39, but it can be slowly pyrophosphorylated by Escherichia
coli phosphoribosyl pyrophosphate (PRPP) synthase with an
excess of PRPP (Km not determined)
40–42, while being a weak
PRPP synthase inhibitor (IC50¼1 mmol/L).
In 2005, Girardet designed a series of adenosine 50-phosphonate
analogs to mimic naturally occurring adenosine monophosphate43. All
these compounds (43–47, Fig. 8) were evaluated in a cellular hepatitis
C virus (HCV) replication assay. To elucidate the mechanism of action
of these novel adenosine phosphonates, their diphosphonate derivatives
(43a–47a, Fig. 8) were also synthesized. Extensive nucleotide
Figure 6 Structures of the 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) and its cyclic form as potential
drug candidates against poxvirus infections.
Table 3 Sructures and activities of amidate prodrugs of PMEA and PMPA.
Compd. R1 R2 R3 EC50
a HIV-1
MT4
EC50
a HIV-2
MT4
CC50
b HIV-1
MT4
EC50
a HIV-1
CEM
EC50
a HIV-2
CEM
CC50
b HIV-2
CEM
36a CH3 OH OH 2.3 1.4 197 3.67 3.67 Z250
36b H OH OH 7.0 7.5 144 7.0 10 69
36c CH3 L-Ala-Me-
ester
PhO 0.029 0.026 71.4 0.053 0.090 27
36d CH3 Gly-Me-ester PhO 0.58 0.15 102 0.23 0.31 88.5
36e CH3 D-Ala-MPhe-
ester
0.99 0.65 213 0.5 0.38 125
36f CH3 L-Phe-Me-
ester
pCl-
PhO
0.04 0.07 64 0.07 0.06 26
36g CH3 L-Ala-Me-
ester
pCl-
PhO
0.15 0.26 57 0.2 0.12 106
36h CHPhP O O 4.9 Z250 4.0 4.0 4250
36i H L-Ala-Me-
ester
PhO 0.23 0.15 5.1 0.12 0.20 3.7
36j H Gly-Me-ester PhO 3.6 4.8 120 5.6 4.5 80
36k H D-Ala-Me-
ester
PhO 15 7.2 120 5.0 6.0 67
aAnti-HIV-1 activity (EC50): 50% effective concentration in wild-type CEM cell cultures (μmol/L).
bCC50: cytotoxic concentration (μmol/L).
Changyuan Wang et al.436incorporation assays by HCV NS5B RNA-dependent RNA polymer-
ase showed that 44a and 45a can serve as chain terminators, whereas
compounds 43a, 46a, and 47a are competitive inhibitors with ATP.Additional steady-state kinetic analysis determined the incorporation
efﬁciency of 44a and 45a as well as the inhibition constants for 43a,
46a, and 47a. In summary, these AMP mimics demonstrated some
Table 4 Chemical stability and biological activities of compounds 37a–d and 38a–c.
Compd. X R Half-life (h)a EC50
b BchE Biological activity in CEM/O cells
pH 7.3 pH 2.0 EC50 CC50
c
HIV-1 HIV-2
37a O H 0.09 n.dd 450 n.dd n.dd n.dd
37b O 3-Me 0.56 n.d 450 n.dd n.dd n.dd
37c O 3-t-Bu 4.05 23.7 450 3.0 4.5 29
37d O 3.5-t-Bu 3.05 9.6 450 5.5 5.3 17
38a N 6-F 1.3 n.d 450 28 26 244
38b N H 4.0 9.6 450 20 21 183
38c N 3-Me 21.3 29.0 450 29 56 4250
PMEA 10 10 50
aHydrolysis in 25 mmol/L phosphate buffer at 37 1C or 25 mmol/L citrate buffer, at 37 1C , half-life (t1/2) were determined from the decreasing
peak of the starting phosphate triester and are the mean of duplicate experiments.
bAnti-HIV-1 activity (EC50): 50% effective concentration in wild-type CEM cell cultures (μmol/L).
cCC50: cytotoxic concentration.
dNot determined due to low chemical stability.
Table 5 Calculated half life of the derivatives 39a, 39b, 40a,
40b compared with PMEA and (R)-PMPA.
Compd. t1/2 (h)
Buffersa PMI-1640 Cuture
medium
Total cell
extracts
39a Stableb 472 472 472
39b Stable 472 472
40a Stable 472 5.3c
40b Stable 472 1.3c 24c
PMEA Stable 472 472 472
(R)-PMEA Stable 472 472 472
apH of the buffers: 1.2, 5.2, 7.4, 8.1, 9.0, 11.5.
bLess than 5% decomposition after 72 h.
cSingle product of decomposition: 39a from 40a and 39b from
40b.
Figure 7 Structures of carbocyclic phosphonate analogs of dideoxy-
adenine nucleotides.
Adenine: an important drug scaffold for antiviral agents 437promising but relatively weak anti-HCV activity. The structural
modiﬁcations on the ribose and around the 50-moiety in this study
are not sufﬁcient to improve a chain terminator's catalytic efﬁciency,nor the binding afﬁnity to NS5B RdRp. Further optimizations are
needed to identify novel and potent nucleoside phosphonate chain
terminators for HCV.
Previous studies proved that PGK was a key step of glyco-
lytic pathway by catalyzing the conversion of 1,3-BPG to
3-phosphoglycerate. Therefore, development of new inhibitors of
parasitic PGK is an attractive approach for drug design. Thus
bisphosphonate analogs of 1,3-bisphospho-D-glyceric acid (1,3-
BPG, 48, Fig. 8), in which the CF2 groups were used in the synthesis
of phosphate mimics, were investigated for the activity against the
phosphoglycerate kinase (PGK)44. Interestingly, most of these
analogs were effective. In addition, compound 48 (Fig. 8) was co-
crystallized with PGK of Trypanosoma brucei and afforded new
insights into the catalytic domain of the parasitic enzyme.
In 2008, Boojamra discovered a well-known nucleoside phos-
phonate reverse transcriptase (RT) inhibitor GS-9148 (4, Fig. 1),
which was active against wild-type HIV at 12 mmol/L9–11. Unlike
many clinical RT inhibitors, relevant reverse transcriptase mutants
(M184V, K65R and 6-TAMS) maintain a susceptibility to 20-
Figure 8 Structures of adenosine 50-phosphonate analogs.
Figure 9 Structures of GS9148 analogs.
Changyuan Wang et al.438
Adenine: an important drug scaffold for antiviral agents 439Fd4AP that is similar to wild-type virus. The 20-ﬂuorine group was
rationally designed into the molecule to improve the selectivity
proﬁle and in preliminary studies using HepG2 cells, compound
GS-9148 showed no measurable effect on the mitochondrial DNA
content, indicating a low potential for mitochondrial toxicity.
With these promising results available, one year later,
Boojamra45 synthesized a family of cyclopentyl-substituted ana-
logs as more potent HIV reverse transcriptase (RT) inhibitors. In
cell cultures, the parent phosphonate diacid 50b demonstrated
moderate antiviral activity (EC50¼16 μmol/L) within 2-fold of
that of GS-9148, and within 5-fold of that of PMPA. In vitro,
cellular metabolism studies using 50b also conﬁrmed that the
active diphosphate metabolite was produced albeit at a lower
efﬁciency relative to GS-9148.
Also based on GS-9148, Mackman12 designed a series of
amidate prodrugs (4, 51a–e, Fig. 9) to effectively deliver GS-
9148 and its active phosphorylated metabolite 51a into targeted
cells. Among these compounds, the ethylalaninyl phosphonami-
date prodrug 4 demonstrated favorable cathepsin A substrate
properties, in addition to favorable in vitro intestinal and hepatic
stabilities. Following oral dosing (3 mg/kg) in Beagle dogs, high
levels (49.0 μmol/L) of active metabolite 51a were observed in
PBMCs, validating the prodrug design strategy and leading to the
nomination of 4 as a clinical candidate.
More recently, a series of 20-ﬂuorine-modiﬁed nucleoside
phosphonates with either an unsaturated C¼C (52, Fig. 10) or a
saturated C–C (53, Fig. 10) phosphonate linker have been prepared
by Mackman as potential inhibitors of HCV polymerase46. The
diphosphate analogs (NTP equivalents) of such compounds were
found to be potent inhibitors of NS5B polymerase (EC50 as low as
2 μmol/L), but the parent compounds (e.g., compounds 7 and 8)
were still weak to inhibit the NS5B polymerase. Clearly, prodrugs
of the parent nucleoside phosphonates improved the cellular
activity.Figure 10 Structures of 20-ﬂuorine-modiﬁed nucleoside phospho-
nates 52 and 53.
Figure 11 Structures of phospTo bypass the thymidine kinase (TK) dependence of the parent
nucleoside analogs, a series of phosphoramidate ProTides (54a–c,
Fig. 11) were designed and synthesized by Herdewijn47 in 2013.
Phosphoramidate derivative pivaloyloxymethyl iminodiacetate
(54b, IDA–POM) exhibited anti-HSV-1 and anti-VZV activity in
cell cultures. L-alanine methyl ester and secondary amine IDA–
POM ester were found to be equally potent against VZV. In
addition, some success was achieved in delivering the nucleoside
monophosphate intracellularly for phosphoramidate compounds
bearing the IDA–POM moiety against VZV to bypass the
thymidine kinase pathway, indicating the POM moiety is a
potential carboxyl protecting group in the design of prodrugs.
However, the application of the phosphoramidate ProTide tech-
nology was only partly successful because none of these com-
pounds showed a signiﬁcant increase in antiviral activity against
the TK-deﬁcient virus strains.
A novel adenine derivative FMCA (55, Fig. 12) bearing a 20-
ﬂuoro-60-methylene-carbocycle was synthesized and evaluated for
its anti-HBV activity by Wang48 in 2011. This compound
demonstrated signiﬁcant antiviral activity against wild-type as
well as lamivudine, adefovir and dual lamivudine/entecavir
resistant mutants. In view of these promising anti-HBV activities,
further biological and biochemical studies of the nucleoside 55
was warranted to assess its full potential as an anti-HBV agent.
In 2013, Rawal49 discovered the other famous 20-ﬂuoro-60-
methylene-carbocyclic adenosine monophosphate prodrug 56
(FMCAP, Fig. 12) and evaluated its in vitro anti-HBV potency
against a lamivudine–entecavir resistant clone (L180Mþ
M204VþS202G). FMCA demonstrated signiﬁcant antiviral activi-
ty against wild-type as well as lamivudine–entecavir resistant triple
mutant (L180MþM204VþS202G). In contrast, the monopho-
sphate prodrug (FMCAP) showed more than 12-fold increase in
anti-HBV activity, without increasing the cellular toxicity. Mito-
chondrial and cellular toxicity studies of FMCA showed that therehoramidate ProTides 54a–c.
Figure 12 Structures of novel adenine derivative FMCA
and FMCAP.
Figure 13 Structures of 50-norcarbocyclic adenosine phosphonic
acid 57 and its bis-SATE prodrug 58.
Changyuan Wang et al.440was no signiﬁcant toxicity up to 100 μmol/L. Very recently, their
extensive exploration displayed that FMCAP reduced HBV viral
load in chimeric mice harboring the triple mutants42.
Oh and his co-workers' studies50 showed that both 50-norcar-
bocyclic adenosine phosphonic acid 57 (FMnAP, Fig. 13) and its
bis-SATE prodrug 58 (Fig. 13) belong to the category of
carbocyclic nucleoside analogs where the furanose oxygen is
replaced by a methylene group. Compared with parent FMnAP
57 (EC50¼62 μmol/L, CC50¼70 μmol/L), prodrug 58 enhanced
the anti-HIV activity (EC50¼16.7 μmol/L, CC50¼31.4 μmol/L),
but showed higher cytotoxicity. Probably, this result was caused
by a higher cellular uptake of the prodrug 58 to cells, followed by
the intracellular release of FMnAP.4. Conclusions
Being an excellent antiviral skeleton, adenine was extensively
modiﬁed both on the side chain and on the heterocyclic moiety.
SARs studies indicated that the margins of the structural alteration
are very narrow. Changing the substituents on the adenine nucleus
will signiﬁcantly decrease their antiviral activity. While for the
reason that the structure of the side chain is critical for the
speciﬁcity of antiviral action, only modifying the side chain as
phosphate ester or amide linker is favorable to improve the oral
bioavailability. To further develop this scaffold, one way is to use
prodrugs to increase membrane permeability and bioavailability,
and the other way is to optimize the acyclic chain, which enables
the compounds to adopt a range of conformations to facilitate
binding to not only reverse transcriptases and DNA polymerases
but potentially to other enzymes using nucleotides as substrates or
products. Although a large number of potential drugs or clinical
drugs have been identiﬁed to inhibit various viruses, owing to the
fast virus mutation, searching for more effective agents still
remains urgent. There is no doubt that adenine is a promising
scaffold worthy of further development to identify new antiviral
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